Latest News About Oral Candidiasis

Here are the latest publicly reported findings on oral candidiasis (OC) relevant to current clinical context.

• In hospitalized COVID-19 patients, OC has been observed with notable incidence rates and appears associated with disease severity and concomitant antibiotic or corticosteroid use. Recent retrospective data reported OC in about 17% of hospitalized COVID-19 patients during Alpha/Beta/Delta variant circulation, with higher risk among more severe disease and those receiving antibiotics or steroids. This suggests clinicians should monitor for OC as part of fungal infection risk in this population.[1]

• Reviews and observational studies since 2020 emphasize that OC is an opportunistic infection influenced by local and systemic immune status, oral hygiene, and iatrogenic factors (e.g., antibiotic exposure). In both adults and children with COVID-19, Candida species—primarily Candida albicans—are reported as common culprits, with varying species distribution. This supports a broad consideration of risk factors when evaluating OC in post-COVID patients.[2][8]

• Management remains largely aligned with standard candidiasis guidelines: topical antifungals for mild disease; systemic antifungals (e.g., fluconazole) for moderate to severe cases or refractory disease, with attention to drug interactions and patient-specific factors (e.g., pregnancy, breastfeeding). Broader reviews note safety profiles and sequence of therapy, including alternatives like itraconazole, posaconazole, or voriconazole for recalcitrant cases.[3]

• Beyond COVID-19, OC is commonly linked to immune suppression, denture use, diabetes, antibiotic therapy, and other systemic conditions. Practice guidelines describe typical presentation, diagnostic approaches (clinical and culture), and stepwise antifungal therapy, with emphasis on addressing underlying risk factors to reduce recurrence.[5][3]

• Emerging literature continues to explore risk factors in special populations (e.g., disabled individuals, pediatrics) and to examine shifts in epidemiology and species distribution, though many findings align with established pathogenic mechanisms of OC. Contemporary studies from diverse regions highlight prevalence and risk factor patterns that can inform screening and prevention in high-risk groups.[4][10]

Illustrative takeaway

• For patients with COVID-19 or other immunosuppressive states, maintain a high index of suspicion for OC, particularly if antibiotics or corticosteroids are used; initiate antifungal therapy promptly when OC is diagnosed and address modifiable risk factors (oral hygiene, glycemic control, smoking cessation) to reduce recurrence.[1][2]

If you’d like, I can compile a brief evidence table summarizing incidence, main risk factors, and first-line treatments from these sources, or tailor recommendations for your clinical setting in Prague.

Citations

• OC incidence in hospitalized COVID-19 patients and predictors:.[1]
• OC in adult/pediatric COVID-19 patients and species distribution:.[2]
• Management guidelines and antifungal options:.[3]
• OC risk factors and broader context:.[5]
• Regional risk factor analyses and prevalence studies:.[10]